Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma
Background. Renal cell carcinoma accounts for about 2-3% of all malignant tumors. The prevalence of brain metastases from RCC is less than 20% of cases. Traditionally, whole brain radiotherapy as well as the latest stereotactic radiosurgery improves both survival and local tumor control. These treat...
Saved in:
Main Authors: | Michela Roberto, Maria Bassanelli, Elsa Iannicelli, Silvana Giacinti, Chiara D’Antonio, Anna Maria Aschelter, Paolo Marchetti |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | Case Reports in Oncological Medicine |
Online Access: | http://dx.doi.org/10.1155/2015/629046 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tumor Reduction with Pazopanib in a Patient with Recurrent Lumbar Chordoma
by: Maurício Fernando Silva Almeida Ribeiro, et al.
Published: (2018-01-01) -
Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion
by: Carmine Pinto, et al.
Published: (2025-01-01) -
Advanced Alveolar Soft Part Sarcoma Treated with Pazopanib over Three Years
by: Yoji Shido, et al.
Published: (2017-01-01) -
The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma
by: Jaya Unnithan, et al.
Published: (2007-01-01) -
Metastatic Lesion of the Tibia from Renal Cell Carcinoma
by: Piotr Młodożeniec, et al.
Published: (2021-01-01)